Side-by-side financials for APRE and AZN. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APRE | AZN |
|---|---|---|
| Market cap | - | $286.27 B |
| US-listed rank | - | #48 |
| Net income (latest FY) | -$12.60M | - |
| SEC filings | 425 | 1,004 |
Full pages: Aprea Therapeutics, Inc. and AstraZeneca PLC, or browse the full rankings.